Literature DB >> 27654286

The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1.

Lihong Liu1, Weiming Wang1, Julie Matz2, Chaobaihui Ye1, Lucie Bracq2, Jerome Delon2, Jason T Kimata3, Zhiwei Chen4, Serge Benichou5, Paul Zhou6.   

Abstract

The variable regions (VHHs) of two heavy chain-only antibodies, JM2 and JM4, from llamas that have been immunized with a trimeric gp140 bound to a CD4 mimic have been recently isolated (here referred to as VHH JM2 and VHH JM4, respectively). JM2 binds the CD4-binding site of gp120 and neutralizes HIV-1 strains from subtypes B, C, and G. JM4 binds gp120 and neutralizes HIV-1 strains from subtypes A, B, C, A/E, and G in a CD4-dependent manner. In the present study, we constructed glycosylphosphatidylinositol (GPI)-anchored VHH JM2 and JM4 along with an E4 control and transduced them into human CD4+ cell lines and primary CD4 T cells. We report that by genetically linking the VHHs with a GPI attachment signal, VHHs are targeted to the lipid rafts of the plasma membranes. Expression of GPI-VHH JM4, but not GPI-VHH E4 and JM2, on the surface of transduced TZM.bl cells potently neutralizes multiple subtypes of HIV-1 isolates, including tier 2 or 3 strains, transmitted founders, quasispecies, and soluble single domain antibody (sdAb) JM4-resistant viruses. Moreover, transduction of CEMss-CCR5 cells with GPI-VHH JM4, but not with GPI-VHH E4, confers resistance to both cell-free and T cell-T cell transmission of HIV-1 and HIV-1 envelope-mediated fusion. Finally, GPI-VHH JM4-transduced human primary CD4 T cells efficiently resist both cell-free and T cell-T cell transmission of HIV-1. Thus, we conclude that VHH JM4, when targeted to the lipid rafts of the plasma membrane, efficiently neutralizes HIV-1 infection via both cell-free and T cell-T cell transmission. Our findings should have important implications for GPI-anchored antibody-based therapy against HIV-1. IMPORTANCE: Lipid rafts are specialized dynamic microdomains of the plasma membrane and have been shown to be gateways for HIV-1 budding as well as entry into T cells and macrophages. In nature, many glycosylphosphatidylinositol (GPI)-anchored proteins localize in the lipid rafts. In the present study, we developed GPI-anchored variable regions (VHHs) of two heavy chain-only antibodies, JM2 and JM4, from immunized llamas. We show that by genetically linking the VHHs with a GPI attachment signal, VHHs are targeted to the lipid rafts of the plasma membranes. GPI-VHH JM4, but not GPI-VHH JM2, in transduced CD4+ cell lines and human primary CD4 T cells not only efficiently blocks diverse HIV-1 strains, including tier 2 or 3 strains, transmitted founders, quasispecies, and soluble sdAb JM4-resistant strains, but also efficiently interferes T cell-T cell transmissions of HIV-1 and HIV-1 envelope-mediated fusion. Our findings should have important implications in GPI-anchored antibody-based therapy against HIV-1.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27654286      PMCID: PMC5110191          DOI: 10.1128/JVI.01559-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1.

Authors:  Rajesh Thippeshappa; Patricia Polacino; Monica T Yu Kimata; Edward B Siwak; David Anderson; Weiming Wang; Laura Sherwood; Reetakshi Arora; Michael Wen; Paul Zhou; Shiu-Lok Hu; Jason T Kimata
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

2.  Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16.

Authors:  Lihong Liu; Michael Wen; Weiming Wang; Shumei Wang; Lifei Yang; Yong Liu; Mengran Qian; Linqi Zhang; Yiming Shao; Jason T Kimata; Paul Zhou
Journal:  J Virol       Date:  2011-06-29       Impact factor: 5.103

3.  RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.

Authors:  David L DiGiusto; Amrita Krishnan; Lijing Li; Haitang Li; Shirley Li; Anitha Rao; Shu Mi; Priscilla Yam; Sherri Stinson; Michael Kalos; Joseph Alvarnas; Simon F Lacey; Jiing-Kuan Yee; Mingjie Li; Larry Couture; David Hsu; Stephen J Forman; John J Rossi; John A Zaia
Journal:  Sci Transl Med       Date:  2010-06-16       Impact factor: 17.956

4.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

5.  Trimeric glycosylphosphatidylinositol-anchored HCDR3 of broadly neutralizing antibody PG16 is a potent HIV-1 entry inhibitor.

Authors:  Lihong Liu; Weiming Wang; Lifei Yang; Huanhuan Ren; Jason T Kimata; Paul Zhou
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

6.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

7.  The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Authors:  Matthew Stremlau; Christopher M Owens; Michel J Perron; Michael Kiessling; Patrick Autissier; Joseph Sodroski
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

8.  Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies.

Authors:  Irene A Abela; Livia Berlinger; Merle Schanz; Lucy Reynell; Huldrych F Günthard; Peter Rusert; Alexandra Trkola
Journal:  PLoS Pathog       Date:  2012-04-05       Impact factor: 6.823

9.  HIV-infected T cells are migratory vehicles for viral dissemination.

Authors:  Thomas T Murooka; Maud Deruaz; Francesco Marangoni; Vladimir D Vrbanac; Edward Seung; Ulrich H von Andrian; Andrew M Tager; Andrew D Luster; Thorsten R Mempel
Journal:  Nature       Date:  2012-08-01       Impact factor: 49.962

10.  Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission.

Authors:  Marine Malbec; Françoise Porrot; Rejane Rua; Joshua Horwitz; Florian Klein; Ari Halper-Stromberg; Johannes F Scheid; Caroline Eden; Hugo Mouquet; Michel C Nussenzweig; Olivier Schwartz
Journal:  J Exp Med       Date:  2013-11-25       Impact factor: 14.307

View more
  9 in total

1.  A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.

Authors:  Xiaoran Tang; Hongliang Jin; Yue Chen; Li Li; Yuanmei Zhu; Huihui Chong; Yuxian He
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

Review 2.  Exploring cellular biochemistry with nanobodies.

Authors:  Ross W Cheloha; Thibault J Harmand; Charlotte Wijne; Thomas U Schwartz; Hidde L Ploegh
Journal:  J Biol Chem       Date:  2020-08-31       Impact factor: 5.157

3.  Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice.

Authors:  Xilin Wu; Jia Guo; Mengyue Niu; Minghui An; Li Liu; Hui Wang; Xia Jin; Qi Zhang; Ka Shing Lam; Tongjin Wu; Hua Wang; Qian Wang; Yanhua Du; Jingjing Li; Lin Cheng; Hang Ying Tang; Hong Shang; Linqi Zhang; Paul Zhou; Zhiwei Chen
Journal:  J Clin Invest       Date:  2018-04-23       Impact factor: 14.808

4.  Glycosyl-Phosphatidylinositol-Anchored Anti-HIV Env Single-Chain Variable Fragments Interfere with HIV-1 Env Processing and Viral Infectivity.

Authors:  Anisha Misra; Emile Gleeson; Weiming Wang; Chaobaihui Ye; Paul Zhou; Jason T Kimata
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

Review 5.  Single-Domain Antibodies As Therapeutics against Human Viral Diseases.

Authors:  Yanling Wu; Shibo Jiang; Tianlei Ying
Journal:  Front Immunol       Date:  2017-12-13       Impact factor: 7.561

6.  Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy.

Authors:  Hongliang Jin; Xiaoran Tang; Li Li; Yue Chen; Yuanmei Zhu; Huihui Chong; Yuxian He
Journal:  Cell Mol Immunol       Date:  2021-01-18       Impact factor: 11.530

7.  Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy.

Authors:  Yue Chen; Hongliang Jin; Xiaoran Tang; Li Li; Xiuzhu Geng; Yuanmei Zhu; Huihui Chong; Yuxian He
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 7.163

Review 8.  Nanobodies that Neutralize HIV.

Authors:  Robin A Weiss; C Theo Verrips
Journal:  Vaccines (Basel)       Date:  2019-07-31

9.  Function-based high-throughput screening for antibody antagonists and agonists against G protein-coupled receptors.

Authors:  Huanhuan Ren; Jian Li; Ning Zhang; Liaoyuan A Hu; Yingli Ma; Philip Tagari; Jianqing Xu; Mei-Yun Zhang
Journal:  Commun Biol       Date:  2020-03-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.